This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll more

Move beyond the threshold with Esperoct®

Esperoct® offers patients with haemophilia A a treatment tailored to their needs with higher FVIII activity levels and low ABR allowing them to move beyond the conventional limitations of haemophilia A1-4.
Take life on with Refixia®

Refixia® is an extended half-life recombinant FIX used in routine prophylaxis as well as for bleed control and surgical procedure for HB patients5. Refixia® once weekly prophylaxis gives your patient the confidence to live beyond haemophilia B maintaining high FIX activity level in the non-haemophilia range most of the time5-9.
Trust in the experience of NovoSeven® —eptatcog alfa

Over 30 years of research and clinical experience10,11 NovoSeven® supporting your patients in more indications than any other bypassing agent.10-14
NovoEight®—turoctocog alfa

Give your patients the path to explore life with NovoEight®.18
NovoThirteen®—catridecacog

The first and only recombinant therapy for congenital FXIII A-subunit deficiency.15-17,19

Discover Live Unlimited

Sickle cell disease (SCD) is a group of life-threatening, inherited red blood cell disorders, and people living with sickle cell disease face significant unmet needs. With our Live Unlimited initiative, we are committed to a future where it is possible to Live Unlimited with SCD.
Discover Live Unlimited

Sickle cell disease (SCD) is a group of life-threatening, inherited red blood cell disorders, and people living with sickle cell disease face significant unmet needs. With our Live Unlimited initiative, we are committed to a future where it is possible to Live Unlimited with SCD.

With Changing Haemophilia® we address the unmet needs in haemophilia and other rare bleeding disorders. Together with you and our community partners, we are striving for better access to care, diagnosis and multidisciplinary care.
Changing Haemophilia
Changing Haemophilia

With Changing Haemophilia® we address the unmet needs in haemophilia and other rare bleeding disorders. Together with you and our community partners, we are striving for better access to care, diagnosis and multidisciplinary care.
Diease area

For people living with a rare disease, the lack of awareness and treatment options can make the entire experience extremely challenging and uncertain. Though each rare disease is complex and challenging to diagnose and manage, they do share many commonalities.
Diease area

For people living with a rare disease, the lack of awareness and treatment options can make the entire experience extremely challenging and uncertain. Though each rare disease is complex and challenging to diagnose and manage, they do share many commonalities.

Resources for treaters of rare bleeding disorders. Here you can find information and resources around haemophilia and in rare blood disorders.
BloodMDResources
BloodMDResources

Resources for treaters of rare bleeding disorders. Here you can find information and resources around haemophilia and in rare blood disorders.

Move beyond the threshold with Esperoct®

Discover all our scientific content for ASH on Science hub, featuring our scientific presentations, recordings, and the complete Novo Nordisk program, and much more.
Haemophilia

Read the most recent articles and congress materials including upcoming congresses related to haemophilia.
Sickle cell disease

Check out the latest articles, congress materials and details on upcoming congresses within sickle cell disease.

1.

Esperoct® Summary of Product Characteristics, 2024.

2.

Chowdary P et al. Res Pract Thromb Haemost 2019; 3:542–554.

3.

Giangrande P et al. J Thromb Haemost 2017; 117:252–261.

4.

Giangrande P et al. J Thromb Haemost 2020; 18:5–14

5.

Refixia® Summary of Product Characteristics, 2022.

6.

Collins PW et al. Blood 2014; 124:3880–3886.

7.

Negrier C et al. Haemophilia 2016; 22:507–513.

8.

Tiede A et al. Haemophilia 2017; 23:547–555.

9.

Young G et al. Thromb Res 2016; 141:69–76.

10.

NovoSeven® Summary of Product Characteristics.

11.

Hedner U. Blood Rev 2015;29(S1):S4-S8.

12.

Hemlibra® Summary of Product Characteristics.

13.

FEIBA® Summary of Product Characteristics.

14.

Obizur® Summary of Product Characteristics.

15.

Carcao M, Altisent C, Castaman G et al. Thromb Haemost 2018;118(3):451-460.

16.

Carcao M, Fukutake K, Inbal A et al. Semin Thromb Hemost 2017;43(1):59-68.

17.

Dorey E. Nat Biotechnol 2014;32:210.

18.

NovoEight® Summary of Product Characteristics.

19.

NovoThirteen® Summary of Product Characteristics.

 


The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.

 

HQ24NNG00184, November 2024

 

Novo Nordisk Healthcare AG, Zurich, Switzerland